PMID- 30782187
OWN - NLM
STAT- MEDLINE
DCOM- 20190611
LR  - 20211204
IS  - 1476-4598 (Electronic)
IS  - 1476-4598 (Linking)
VI  - 18
IP  - 1
DP  - 2019 Feb 19
TI  - Targeting PI3K in cancer: mechanisms and advances in clinical trials.
PG  - 26
LID - 10.1186/s12943-019-0954-x [doi]
LID - 26
AB  - Phosphatidylinositol-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) 
      signaling is one of the most important intracellular pathways, which can be 
      considered as a master regulator for cancer. Enormous efforts have been dedicated 
      to the development of drugs targeting PI3K signaling, many of which are currently 
      employed in clinical trials evaluation, and it is becoming increasingly clear 
      that PI3K inhibitors are effective in inhibiting tumor progression. PI3K 
      inhibitors are subdivided into dual PI3K/mTOR inhibitors, pan-PI3K inhibitors and 
      isoform-specific inhibitors. In this review, we performed a critical review to 
      summarize the role of the PI3K pathway in tumor development, recent PI3K 
      inhibitors development based on clinical trials, and the mechanisms of resistance 
      to PI3K inhibition.
FAU - Yang, Jing
AU  - Yang J
AD  - Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of 
      Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, 
      West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China.
FAU - Nie, Ji
AU  - Nie J
AD  - Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of 
      Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, 
      West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China.
FAU - Ma, Xuelei
AU  - Ma X
AD  - Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of 
      Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, 
      West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China.
FAU - Wei, Yuquan
AU  - Wei Y
AD  - Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of 
      Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, 
      West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China.
FAU - Peng, Yong
AU  - Peng Y
AD  - Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of 
      Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, 
      West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China.
FAU - Wei, Xiawei
AU  - Wei X
AD  - Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of 
      Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, 
      West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China. 
      xiaweiwei@scu.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20190219
PL  - England
TA  - Mol Cancer
JT  - Molecular cancer
JID - 101147698
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Phosphoinositide-3 Kinase Inhibitors)
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Drug Resistance, Neoplasm/genetics
MH  - *Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Molecular Targeted Therapy/*methods
MH  - Neoplasms/*drug therapy/enzymology/genetics/pathology
MH  - Phosphatidylinositol 3-Kinases/*genetics/metabolism
MH  - Phosphoinositide-3 Kinase Inhibitors
MH  - Protein Kinase Inhibitors/*therapeutic use
MH  - Proto-Oncogene Proteins c-akt/genetics/metabolism
MH  - Signal Transduction
MH  - TOR Serine-Threonine Kinases/genetics/metabolism
PMC - PMC6379961
OTO - NOTNLM
OT  - Cancer
OT  - PI3K
OT  - Target therapy
OT  - mTOR
COIS- AUTHORS' INFORMATION: Not applicable. ETHICS APPROVAL AND CONSENT TO PARTICIPATE: 
      Not applicable. CONSENT FOR PUBLICATION: Not applicable. COMPETING INTERESTS: The 
      authors declare that they have no competing interests. PUBLISHER'S NOTE: Springer 
      Nature remains neutral with regard to jurisdictional claims in published maps and 
      institutional affiliations.
EDAT- 2019/02/21 06:00
MHDA- 2019/06/14 06:00
PMCR- 2019/02/19
CRDT- 2019/02/21 06:00
PHST- 2019/01/02 00:00 [received]
PHST- 2019/02/06 00:00 [accepted]
PHST- 2019/02/21 06:00 [entrez]
PHST- 2019/02/21 06:00 [pubmed]
PHST- 2019/06/14 06:00 [medline]
PHST- 2019/02/19 00:00 [pmc-release]
AID - 10.1186/s12943-019-0954-x [pii]
AID - 954 [pii]
AID - 10.1186/s12943-019-0954-x [doi]
PST - epublish
SO  - Mol Cancer. 2019 Feb 19;18(1):26. doi: 10.1186/s12943-019-0954-x.